[Andrological, biochemical and endocrinological studies of subfertile men during kallikrein therapy].
31 men with idiopathic oligozoospermia and 23 men with idiopathic asthenozoospermia were treated three months by oral administration of daily 600 units kallikrein. In a greater number of patients apart from the semen analysis different seminal plasma proteins and enzymes as well as hormones in serum (LH, FSH, prolactin, testosterone) and in seminal plasma (LH, prolactin) were determined. There was a significant increase of sperm count and sperm motility in the oligozoospermic group. In asthenozoospermic patients sperm motility was significantly increased, however, sperm count decreased within the normal range. Conception rate was 25% in the oligozoospermic goup and 36% in the asthenozoospermic group. A treatment period of three months showed better results than seven weeks and a dosage of 600 units kallikrein daily was significantly better than daily 300 units. During kallikrein therapy mean concentrations of alpha U,x-antichymotrypsin in seminal plasma and serum LH, prolactin and testosterone increased significantly. Seminal plasma levels of LH and prolactin remained unchanged. The mode of action of systemic kallikrein therapy may be at the level of tissue hormones (kinin liberation), however, an increase of the intratesticular testosterone level and an interference with the blood-seminal plasma barrier has also to be considered.
D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007610:Kallikreins / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009845:Oligospermia / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D011506:Proteins / Q000032:analysis; D012661:Semen / Q000032:analysis; D013076:Sperm Count; D013739:Testosterone / Q000097:blood
D011506:Proteins; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D007610:Kallikreins
Andrologische, biochemische und endokrinologische Untersuchungen bei subfertilen Männern während Kallikreintherapie.